IP Library › Granted Patent US 11,760,763
Granted Patent B2
US 11,760,763 · App. 17/477,649 · Granted Sep 19, 2023

Heteroaryl compounds useful as MK2 inhibitors

Inventors: Jian Guo (Lexington, MA); John Malona (Brookline, MA); Alexander L. Ruchelman (Cream Ridge, NJ); Sekhar S. Surapaneni (Warren, NJ)
Assignee: Bristol-Myers Squibb Company
C07D495/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,760,763
App. No.
17/477,649
Granted
Sep 19, 2023
Kind
B2
Abstract

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Claims (15)

1. A compound of Formulae V, V′, or V″:

or a pharmaceutically acceptable salt thereof, wherein:

each of R 7 , R 7′ , R 8 , R 8′ , R 8″ , R 9 , R xa , R xb , R ya , and K yb is independently hydrogen or deuterium

wherein the compound is other than:

2. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable adjuvant, carrier, or vehicle.

4. A pharmaceutical composition comprising a compound according to claim 2 , and a pharmaceutically acceptable adjuvant, carrier, or vehicle.

5. The compound according to claim 1 , wherein each of R xa , R xb , R ya , and R yb is hydrogen.

6. The compound according to claim 1 , wherein each of R xa , R xb , R ya and R yb is deuterium.

7. The compound according to claim 1 , wherein each of R 7 , R 7′ , R 8 , R 8′ , R 8″ , and R 9 is hydrogen.

8. The compound according to claim 6 , wherein each of R 7 , R 7′ , R 8′ , R 8″ , and R 9 is hydrogen.

9. The compound according to claim 1 , wherein each of R 7 , R 7′ , R 8 , R 8′ , R 8″ , and R 9 is deuterium.

10. The compound according to claim 5 , wherein each of R 7 , R 7′ , R 8 , R 8′ , R 8″ , and R 9 is deuterium.

11. The compound according to claim 6 , wherein each of R 7 , R 7′ , R 8 , R 8′ , R 8″ , and R 9 is deuterium.

Assignments (2)
NUNC PRO TUNC ASSIGNMENT Recorded May 3, 2023
From: CELGENE CAR LLC
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 063526/0959 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2021
From: GUO, JIAN; MALONA, JOHN; RUCHELMAN, ALEXANDER L.; SURAPANENI, SEKHAR S.
To: CELGENE CAR LLC
Reel/Frame 057528/0532 →
Continuity (3)
Division 16494690
Provisional Application 62472019 · Mar 16, 2017
Related Publication 20220064183A1 · Mar 3, 2022